Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment
- PMID: 29337638
- DOI: 10.1200/JCO.2017.76.0983
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment
Comment in
-
Reply to M. Horiguchi et al.J Clin Oncol. 2018 Mar 1;36(7):722-723. doi: 10.1200/JCO.2017.76.5347. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337635 No abstract available.
-
Reply to M. Horiguchi et al.J Clin Oncol. 2018 Mar 1;36(7):721. doi: 10.1200/JCO.2017.76.5339. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337639 No abstract available.
Comment on
-
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25. J Clin Oncol. 2017. PMID: 28841387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical